US4855134A
(en)
*
|
1983-10-14 |
1989-08-08 |
Sumitomo Pharmaceuticals Company, Limited |
Sustained-release preparation
|
EP0138216B1
(de)
*
|
1983-10-14 |
1993-01-07 |
Sumitomo Pharmaceuticals Company, Limited |
IFN-Präparat mit verzögerter Abgabe für parentale Verabreichung
|
US5385738A
(en)
*
|
1983-10-14 |
1995-01-31 |
Sumitomo Pharmaceuticals Company, Ltd. |
Sustained-release injection
|
US4774091A
(en)
*
|
1983-10-14 |
1988-09-27 |
Sumitomo Pharmaceuticals Company, Ltd. |
Long-term sustained-release preparation
|
JPS60176586A
(ja)
*
|
1984-02-21 |
1985-09-10 |
Sanwa Kagaku Kenkyusho:Kk |
新規な修飾ウロキナ−ゼ、その製法並びにこれを含有する血栓溶解剤
|
DE3572982D1
(en)
*
|
1984-03-06 |
1989-10-19 |
Takeda Chemical Industries Ltd |
Chemically modified lymphokine and production thereof
|
GB8430252D0
(en)
*
|
1984-11-30 |
1985-01-09 |
Beecham Group Plc |
Compounds
|
DE3500180A1
(de)
*
|
1985-01-04 |
1986-07-10 |
Ernst Prof. Dr. 7400 Tübingen Bayer |
Pfropfcopolymerisate aus vernetzten polymeren und polyoxyethylen, verfahren zu ihrer herstellung und ihre verwendung
|
US4713240A
(en)
*
|
1985-04-04 |
1987-12-15 |
Research Corporation |
Vaccines based on insoluble supports
|
US5206344A
(en)
*
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
US4766106A
(en)
*
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
JP2524586B2
(ja)
*
|
1985-06-26 |
1996-08-14 |
シタス コーポレイション |
ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
|
ES2054613T3
(es)
*
|
1985-12-27 |
1994-08-16 |
Sumitomo Pharma |
Un metodo para preparar una formulacion de liberacion mantenida.
|
JP2514950B2
(ja)
*
|
1986-03-10 |
1996-07-10 |
エフ・ホフマン―ラ ロシユ アーゲー |
化学修飾蛋白質,その製造法および中間体
|
US5017370A
(en)
*
|
1986-05-15 |
1991-05-21 |
Emory University |
Improved method of performing angioplasty procedures
|
US5032394A
(en)
*
|
1986-05-15 |
1991-07-16 |
Emory University |
Method of treating burns
|
US5080894A
(en)
*
|
1986-05-15 |
1992-01-14 |
Emory University |
Method and composition for reducing tissue damage
|
US5152979A
(en)
*
|
1986-05-15 |
1992-10-06 |
Emory University |
Method for treating vascular obstructions caused by abnormal cells
|
US5064643A
(en)
*
|
1986-05-15 |
1991-11-12 |
Emory University |
Method for treating sickle cell disease
|
US5030448A
(en)
*
|
1986-05-15 |
1991-07-09 |
Emory University |
Method of delivering drugs to damaged or diseased tissue
|
US5078995A
(en)
*
|
1986-05-15 |
1992-01-07 |
Emory University |
Fibrionolytic composition
|
US5071649A
(en)
*
|
1986-05-15 |
1991-12-10 |
Emory University |
Method of preventing blockage in catheters
|
US4937070A
(en)
*
|
1986-05-15 |
1990-06-26 |
Emory University |
Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
|
US5039520A
(en)
*
|
1986-05-15 |
1991-08-13 |
Emory University |
Plasma extender
|
EP0498470B1
(de)
*
|
1986-05-15 |
1996-09-11 |
Emory University |
Injizierbares Arzneimittel zum Schutz vor Gewebebeschädigung durch Ischemie
|
US4873083A
(en)
*
|
1986-05-15 |
1989-10-10 |
Emory University |
Fibrinolytic composition
|
US5198211A
(en)
*
|
1986-05-15 |
1993-03-30 |
Emory University |
Method of treating myocardial damage
|
US5648071A
(en)
*
|
1986-05-15 |
1997-07-15 |
Emory University |
Method of treating tumors
|
US5240701A
(en)
*
|
1986-05-15 |
1993-08-31 |
Emory University |
Method of performing angioplasty procedures
|
US5028599A
(en)
*
|
1986-05-15 |
1991-07-02 |
Emory University |
Method of treating mycardial damage
|
US4997644A
(en)
*
|
1986-05-15 |
1991-03-05 |
Emory University |
Method of treating adult respiratory distress syndrome
|
US5041288A
(en)
*
|
1986-05-15 |
1991-08-20 |
Emory University |
Method of treating tissue damaged by reperfusion injury
|
US4879109A
(en)
*
|
1986-05-15 |
1989-11-07 |
Emory University |
Method for treating burns
|
US5182106A
(en)
*
|
1986-05-15 |
1993-01-26 |
Emory University |
Method for treating hypothermia
|
US4897263A
(en)
*
|
1986-05-15 |
1990-01-30 |
Emory University |
Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
|
US5089260A
(en)
*
|
1986-05-15 |
1992-02-18 |
Emory University |
Method of treating ischemic tissue
|
WO1987006831A1
(en)
*
|
1986-05-15 |
1987-11-19 |
Emory University |
Composition and method for treating a thrombus and embolus
|
US4801452A
(en)
*
|
1986-05-15 |
1989-01-31 |
Hunter Robert L |
Fibrinolytic composition
|
US4837014A
(en)
*
|
1986-05-15 |
1989-06-06 |
Emory University |
An improved method of treating sickle cell anemia
|
CA1283046C
(en)
*
|
1986-05-29 |
1991-04-16 |
Nandini Katre |
Tumor necrosis factor formulation
|
US5037969A
(en)
*
|
1986-07-03 |
1991-08-06 |
Takeda Chemical Industries, Ltd. |
Glycosyl derivatives and use thereof
|
GR871067B
(en)
*
|
1986-07-18 |
1987-11-19 |
Chugai Pharmaceutical Co Ltd |
Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
|
US4931544A
(en)
*
|
1986-09-04 |
1990-06-05 |
Cetus Corporation |
Succinylated interleukin-2 for pharmaceutical compositions
|
US5554372A
(en)
*
|
1986-09-22 |
1996-09-10 |
Emory University |
Methods and vaccines comprising surface-active copolymers
|
US4929442A
(en)
*
|
1986-09-26 |
1990-05-29 |
Exovir, Inc. |
Compositions suitable for human topical application including a growth factor and/or related materials
|
US5674911A
(en)
*
|
1987-02-20 |
1997-10-07 |
Cytrx Corporation |
Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
|
US5811088A
(en)
*
|
1987-02-20 |
1998-09-22 |
Emory University |
Antiinfective compounds and methods of use
|
EP0390849B1
(de)
*
|
1987-12-03 |
1993-01-07 |
The Liposome Company, Inc. |
Arzneimittel mit methylcellulose
|
US4847325A
(en)
*
|
1988-01-20 |
1989-07-11 |
Cetus Corporation |
Conjugation of polymer to colony stimulating factor-1
|
US5349052A
(en)
*
|
1988-10-20 |
1994-09-20 |
Royal Free Hospital School Of Medicine |
Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
|
US6132763A
(en)
*
|
1988-10-20 |
2000-10-17 |
Polymasc Pharmaceuticals Plc |
Liposomes
|
GB8824591D0
(en)
|
1988-10-20 |
1988-11-23 |
Royal Free Hosp School Med |
Fractionation process
|
US5011486A
(en)
*
|
1988-11-18 |
1991-04-30 |
Brown University Research Foundation |
Composite nerve guidance channels
|
US5510418A
(en)
*
|
1988-11-21 |
1996-04-23 |
Collagen Corporation |
Glycosaminoglycan-synthetic polymer conjugates
|
US5162430A
(en)
*
|
1988-11-21 |
1992-11-10 |
Collagen Corporation |
Collagen-polymer conjugates
|
US5306500A
(en)
*
|
1988-11-21 |
1994-04-26 |
Collagen Corporation |
Method of augmenting tissue with collagen-polymer conjugates
|
US5565519A
(en)
*
|
1988-11-21 |
1996-10-15 |
Collagen Corporation |
Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
|
WO1990005534A1
(en)
*
|
1988-11-23 |
1990-05-31 |
Genentech, Inc. |
Polypeptide derivatives
|
ATE135370T1
(de)
*
|
1988-12-22 |
1996-03-15 |
Kirin Amgen Inc |
Chemisch modifizierte granulocytenkolonie erregender faktor
|
US20020177688A1
(en)
*
|
1988-12-22 |
2002-11-28 |
Kirin-Amgen, Inc., |
Chemically-modified G-CSF
|
WO1990009798A1
(en)
*
|
1989-02-24 |
1990-09-07 |
Immunotherapeutics, Inc. |
Immobilized cytokines
|
US5122614A
(en)
*
|
1989-04-19 |
1992-06-16 |
Enzon, Inc. |
Active carbonates of polyalkylene oxides for modification of polypeptides
|
US5324844A
(en)
*
|
1989-04-19 |
1994-06-28 |
Enzon, Inc. |
Active carbonates of polyalkylene oxides for modification of polypeptides
|
US7264944B1
(en)
|
1989-04-21 |
2007-09-04 |
Amgen Inc. |
TNF receptors, TNF binding proteins and DNAs coding for them
|
US5166322A
(en)
*
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
EP0393438B1
(de)
*
|
1989-04-21 |
2005-02-16 |
Amgen Inc. |
TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
|
JP2517760B2
(ja)
*
|
1989-05-11 |
1996-07-24 |
新技術事業団 |
水溶性高分子化医薬製剤
|
IL95031A
(en)
*
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
US6143866A
(en)
*
|
1989-07-18 |
2000-11-07 |
Amgen, Inc. |
Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
|
US5286637A
(en)
*
|
1989-08-07 |
1994-02-15 |
Debiopharm, S.A. |
Biologically active drug polymer derivatives and method for preparing same
|
CA2038935C
(en)
*
|
1989-08-07 |
1998-12-08 |
Luciana Sartore |
Biologically active drug polymer derivatives and method for preparing same
|
US6586222B1
(en)
|
1989-08-16 |
2003-07-01 |
Chiron Corporation |
Recombinant PR-3 and compositions thereof
|
US5998378A
(en)
*
|
1989-08-16 |
1999-12-07 |
Chiron Corporation |
Compositions for the inhibition of TNF hormone formation and uses thereof
|
US5843693A
(en)
*
|
1989-08-16 |
1998-12-01 |
Chiron Corporation |
Assay method for screening for inhibitors of proTNF conversion
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
NZ238731A
(en)
*
|
1990-06-27 |
1996-02-27 |
Univ Emory |
Vaccine adjuvant compositions comprising ethyleneoxy-propyleneoxy-ethyleneoxy block copolymer or a non-toxic lipopolysaccharide
|
IE912365A1
(en)
*
|
1990-07-23 |
1992-01-29 |
Zeneca Ltd |
Continuous release pharmaceutical compositions
|
US6565841B1
(en)
|
1991-03-15 |
2003-05-20 |
Amgen, Inc. |
Pulmonary administration of granulocyte colony stimulating factor
|
US20020123476A1
(en)
*
|
1991-03-19 |
2002-09-05 |
Emanuele R. Martin |
Therapeutic delivery compositions and methods of use thereof
|
US6933286B2
(en)
|
1991-03-19 |
2005-08-23 |
R. Martin Emanuele |
Therapeutic delivery compositions and methods of use thereof
|
KR100224539B1
(ko)
*
|
1991-03-19 |
1999-10-15 |
잭 제이 루체스 |
개선된 생물학적 활성을 가진 폴리옥시프로필렌/폴리옥시에틸렌 공중합체 조성물
|
USRE38558E1
(en)
|
1991-03-19 |
2004-07-20 |
Cytrx Corporation |
Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
|
US5696298A
(en)
*
|
1991-03-19 |
1997-12-09 |
Cytrx Corporation |
Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
|
US7202225B1
(en)
|
1993-10-15 |
2007-04-10 |
Emanuele R Martin |
Therapeutic delivery compositions and methods of use thereof
|
US5595732A
(en)
*
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
CA2102808A1
(en)
|
1991-05-10 |
1992-11-11 |
Hanne Bentz |
Targeted delivery of bone growth factors
|
US5622649A
(en)
*
|
1991-06-27 |
1997-04-22 |
Emory University |
Multiple emulsions and methods of preparation
|
US5605687A
(en)
*
|
1992-05-15 |
1997-02-25 |
Arch Development Corporation |
Methods and compositions of a polymer (poloxamer) for repair of electrical injury
|
US6063764A
(en)
*
|
1992-06-01 |
2000-05-16 |
Washington University & Chiron Corp. |
Method for using lipoprotein associated coagulation inhibitor to treat sepsis
|
US20030171292A1
(en)
*
|
1992-06-01 |
2003-09-11 |
Creasey Abla A. |
Method for using lipoprotein associated coagulation inhibitor to treat sepsis
|
US5278303A
(en)
*
|
1992-06-12 |
1994-01-11 |
University Of Toronto Innovations Foundation |
Polymer-supported solution synthesis of oligosaccharides
|
ZA933926B
(en)
*
|
1992-06-17 |
1994-01-03 |
Amgen Inc |
Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
|
US5382657A
(en)
*
|
1992-08-26 |
1995-01-17 |
Hoffmann-La Roche Inc. |
Peg-interferon conjugates
|
TW263437B
(de)
*
|
1992-09-24 |
1995-11-21 |
Takeda Pharm Industry Co Ltd |
|
US6093391A
(en)
*
|
1992-10-08 |
2000-07-25 |
Supratek Pharma, Inc. |
Peptide copolymer compositions
|
US6277410B1
(en)
|
1992-10-08 |
2001-08-21 |
Supratek Pharma Inc. |
Copolymer compositions for oral delivery
|
US6153193A
(en)
*
|
1993-04-28 |
2000-11-28 |
Supratek Pharma Inc. |
Compositions for targeting biological agents
|
JPH09505721A
(ja)
*
|
1992-10-20 |
1997-06-10 |
シータス オンコロジー コーポレイション |
インターロイキン6レセプターアンタゴニスト
|
US5516703A
(en)
*
|
1993-08-20 |
1996-05-14 |
The University Of Utah |
Coating of hydrophobic surfaces to render them protein resistant while permitting covalent attachment of specific ligands
|
US20070202127A1
(en)
*
|
1993-06-07 |
2007-08-30 |
Duke University |
Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
|
US6479055B1
(en)
*
|
1993-06-07 |
2002-11-12 |
Trimeris, Inc. |
Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
|
US6284503B1
(en)
|
1993-08-20 |
2001-09-04 |
University Of Utah Research Foundation |
Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces
|
US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
AU691225B2
(en)
*
|
1993-11-10 |
1998-05-14 |
Schering Corporation |
Improved interferon polymer conjugates
|
US5616698A
(en)
*
|
1994-01-10 |
1997-04-01 |
University Of Toronto Innovations Foundation |
Polymer-supported solution synthesis of oligosaccharides
|
ES2312166T3
(es)
|
1994-02-23 |
2009-02-16 |
Kyowa Hakko Kogyo Co., Ltd |
Acelerador del crecimiento plaquetario.
|
WO1995024501A1
(en)
|
1994-03-07 |
1995-09-14 |
Cetus Oncology Corporation |
Compositions for the inhibition of tnf formation and uses thereof
|
US5795569A
(en)
*
|
1994-03-31 |
1998-08-18 |
Amgen Inc. |
Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
|
KR100203824B1
(ko)
*
|
1994-03-31 |
1999-06-15 |
스티븐 엠. 오드리 |
거핵구 성장 및 분화를 자극하기 위한 조성물 및방법
|
US5583114A
(en)
|
1994-07-27 |
1996-12-10 |
Minnesota Mining And Manufacturing Company |
Adhesive sealant composition
|
USRE38827E1
(en)
|
1994-07-27 |
2005-10-11 |
3M Innovative Properties Company |
Adhesive sealant composition
|
US20030053982A1
(en)
*
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
US5738846A
(en)
*
|
1994-11-10 |
1998-04-14 |
Enzon, Inc. |
Interferon polymer conjugates and process for preparing the same
|
US6353055B1
(en)
*
|
1994-11-18 |
2002-03-05 |
Supratek Pharma Inc. |
Polynucleotide compositions
|
US6004583A
(en)
*
|
1995-03-22 |
1999-12-21 |
Orex Pharmaceutical Development Corp. |
Protein-containing polymer composition for oral administration
|
US5585484A
(en)
*
|
1995-04-19 |
1996-12-17 |
Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University |
Hemoglobin crosslinkers
|
DE741187T1
(de)
*
|
1995-05-05 |
1997-04-30 |
Hoffmann La Roche |
Rekombinante Obesitäts-(OB)-Proteine
|
US6025324A
(en)
*
|
1996-05-15 |
2000-02-15 |
Hoffmann-La Roche Inc. |
Pegylated obese (ob) protein compositions
|
TW517067B
(en)
*
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
DE69731836T2
(de)
*
|
1996-07-23 |
2005-12-01 |
Pangenetics B.V. |
Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann
|
AU3819297A
(en)
*
|
1996-08-02 |
1998-02-25 |
Orex Pharmaceutical Development Corp. |
Protein-containing polymer composition for oral administration
|
DK1007082T3
(da)
*
|
1997-01-15 |
2007-02-19 |
Phoenix Pharmacologics Inc |
Modificeret tumor nekrose faktor
|
US6183738B1
(en)
|
1997-05-12 |
2001-02-06 |
Phoenix Pharamacologics, Inc. |
Modified arginine deiminase
|
US5981709A
(en)
*
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
US5985263A
(en)
*
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
PL192364B1
(pl)
*
|
1998-06-08 |
2006-10-31 |
Hoffmann La Roche |
Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
|
ATE364654T1
(de)
*
|
1998-08-28 |
2007-07-15 |
Amylin Pharmaceuticals Inc |
Polyamideketten von genauer länge und deren konjugate mit proteinen
|
EA005005B1
(ru)
|
1998-10-16 |
2004-10-28 |
Байоджен, Инк. |
ГИБРИДНЫЙ ПОЛИПЕПТИД β1α-ИНТЕРФЕРОНА ЧЕЛОВЕКА, ЕГО МУТАНТНЫЕ ФОРМЫ И ПРОИЗВОДНЫЕ И СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
|
CN1329082C
(zh)
|
1998-10-16 |
2007-08-01 |
拜奥根Idec马萨诸塞公司 |
干扰素-β-1a的聚合物缀合物及其使用
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
WO2000029431A1
(en)
*
|
1998-11-17 |
2000-05-25 |
Tanox, Inc. |
Bispecific molecules cross-linking itim and itam for therapy
|
US7118743B2
(en)
|
1998-11-17 |
2006-10-10 |
Tanox, Inc. |
Bispecific molecules cross-linking ITIM and ITAM for therapy
|
ATE246202T1
(de)
*
|
1999-01-29 |
2003-08-15 |
Hoffmann La Roche |
Gcsf konjugate
|
IL149267A0
(en)
|
1999-11-12 |
2002-11-10 |
Maxygen Holdings Ltd |
Interferon gamma conjugates
|
YU32402A
(sh)
|
1999-11-12 |
2005-03-15 |
Maxygen Holdings Ltd. |
Konjugati gama interferona
|
US7256180B2
(en)
|
2000-04-28 |
2007-08-14 |
Supratek Pharma Inc. |
Compositions and methods for inducing activation of dendritic cells
|
SG98393A1
(en)
|
2000-05-19 |
2003-09-19 |
Inst Materials Research & Eng |
Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
|
DK1325033T3
(da)
|
2000-10-10 |
2010-04-06 |
Genentech Inc |
Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7038015B2
(en)
|
2001-04-06 |
2006-05-02 |
Maxygen Holdings, Ltd. |
Interferon gamma polypeptide variants
|
US6958388B2
(en)
|
2001-04-06 |
2005-10-25 |
Maxygen, Aps |
Interferon gamma polypeptide variants
|
DE60229958D1
(de)
*
|
2001-06-28 |
2009-01-02 |
Mountain View Pharmaceuticals |
Polymerstabilisierte proteinasen
|
EP3372243A1
(de)
|
2001-08-17 |
2018-09-12 |
Genentech, Inc. |
Komplement-inhibitoren, die an c5 und c5a binden, ohne die bildung von c5b zu hemmen
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
EP1446138A4
(de)
*
|
2001-10-15 |
2007-03-14 |
Novartis Vaccines & Diagnostic |
Behandlung von sepsis durch verabreichung von niedrigen dosen von tfpi (tissue factor pathway inhibitor)
|
WO2003072714A2
(en)
|
2002-02-21 |
2003-09-04 |
Wyeth |
Follistatin domain containing proteins
|
AU2003239774A1
(en)
|
2002-07-03 |
2004-01-23 |
Maxygen Holdings Ltd. |
Full-length interferon gamma polypeptide variants
|
EP1572092A4
(de)
*
|
2002-08-02 |
2007-09-05 |
Wyeth Corp |
Mk2 wechselwirkungs-proteine
|
US8129330B2
(en)
*
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US20040062748A1
(en)
*
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
EP1599217B1
(de)
*
|
2002-11-18 |
2014-04-16 |
Polaris Group |
Verfahren zur verhinderung von virusreplikation in vivo
|
PT1667708E
(pt)
*
|
2002-12-26 |
2012-09-14 |
Mountain View Pharmaceuticals |
Conjugados de interferão-beta-1b e polietileno glicol apresentando uma potência biológica in vitro aumentada
|
EA013535B1
(ru)
*
|
2002-12-26 |
2010-06-30 |
Маунтин Вью Фамэсьютикэлс, Инк. |
Полимерный конъюгат биоактивного компонента (варианты), способ его получения и использования, фармацевтические продукты на его основе
|
EP1603949B9
(de)
*
|
2003-03-14 |
2011-02-02 |
Wyeth LLC |
Antikörper gegen il21-rezeptor und deren verwendung
|
WO2005044855A2
(en)
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
|
EP1844815B1
(de)
|
2003-11-04 |
2011-09-14 |
Novartis Vaccines and Diagnostics, Inc. |
Kombinationstherapie von anti-CD20 und anti-CD40 Antikörpern zur Behandlung von B-Zell-bedingtem Krebs
|
ATE447412T1
(de)
|
2003-11-04 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
|
DE602004028643D1
(de)
|
2003-11-04 |
2010-09-23 |
Novartis Vaccines & Diagnostic |
Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens
|
PL1682177T3
(pl)
|
2003-11-04 |
2011-03-31 |
Novartis Vaccines & Diagnostics Inc |
Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia przewlekłej białaczki limfocytowej
|
JP5422101B2
(ja)
|
2004-01-07 |
2014-02-19 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
M−csf特異的モノクローナル抗体およびその使用
|
US20050169970A1
(en)
*
|
2004-02-02 |
2005-08-04 |
Unilever Bestfoods, North America |
Food composition with fibers
|
AU2005244249A1
(en)
*
|
2004-03-17 |
2005-11-24 |
Novartis Vaccines And Diagnostics, Inc. |
Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (TFPI)
|
EA012205B1
(ru)
*
|
2004-05-17 |
2009-08-28 |
Арес Трейдинг С.А. |
Гидрогелевые препараты интерферона
|
CA2567310A1
(en)
|
2004-06-01 |
2005-12-15 |
Ares Trading S.A. |
Stabilized interferon liquid formulations
|
WO2006015365A1
(en)
*
|
2004-07-30 |
2006-02-09 |
Mount Sinai School Of Medicine Of New York University |
Npc1l1 and npc1l1 inhibitors and methods of use thereof
|
WO2006071441A2
(en)
|
2004-11-30 |
2006-07-06 |
Curagen Corporation |
Antibodies directed to gpnmb and uses thereof
|
NZ561883A
(en)
|
2005-03-23 |
2010-11-26 |
Genmab As |
Antibodies against CD38 for treatment of multiple myeloma
|
US20060269556A1
(en)
*
|
2005-04-18 |
2006-11-30 |
Karl Nocka |
Mast cell activation using siglec 6 antibodies
|
JP2009501913A
(ja)
*
|
2005-07-21 |
2009-01-22 |
ゲンマブ エー/エス |
Fc受容体と結合する抗体原薬に関する効力アッセイ
|
WO2007016240A2
(en)
*
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
Use of antibody to m-csf
|
US8652469B2
(en)
*
|
2005-07-28 |
2014-02-18 |
Novartis Ag |
M-CSF-specific monoclonal antibody and uses thereof
|
US20090155850A1
(en)
*
|
2005-10-28 |
2009-06-18 |
The Florida International University Board Of Trustees |
Horse:Human Chimeric Antibodies
|
US9181344B2
(en)
|
2005-12-15 |
2015-11-10 |
Genmab A/S |
Use of effector-function-deficient antibodies for treatment of auto-immune diseases
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
EP2010569A4
(de)
|
2006-03-20 |
2009-09-09 |
Xoma Technology Ltd |
Für gastrin spezifische humane antikörper, materialien und methoden
|
EP2012827A2
(de)
|
2006-04-13 |
2009-01-14 |
Novartis Vaccines and Diagnostics, Inc. |
Verfahren für behandlung, diagnostizierung bzw. nachweis von krebs
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
US20080096819A1
(en)
*
|
2006-05-02 |
2008-04-24 |
Allozyne, Inc. |
Amino acid substituted molecules
|
US7632492B2
(en)
*
|
2006-05-02 |
2009-12-15 |
Allozyne, Inc. |
Modified human interferon-β polypeptides
|
AU2007276294B2
(en)
|
2006-06-30 |
2012-11-29 |
Novo Nordisk A/S |
Anti-NKG2A antibodies and uses thereof
|
KR101437188B1
(ko)
*
|
2006-08-04 |
2014-10-02 |
노바르티스 아게 |
Ephb3-특이적 항체 및 이의 용도
|
AR062435A1
(es)
|
2006-08-18 |
2008-11-05 |
Xoma Technology Ltd |
Anticuerpo especifico prlr (receptor de prolactina) y sus usos
|
MX2009006034A
(es)
|
2006-12-07 |
2009-10-12 |
Novartis Ag |
Anticuerpos antagonistas contra ephb3.
|
GB0700133D0
(en)
|
2007-01-04 |
2007-02-14 |
Humabs Llc |
Human cytomegalovirus neutralising antibodies and use thereof
|
MX2009008104A
(es)
|
2007-02-02 |
2009-08-07 |
Amgen Inc |
Hepcidina, antagonistas de hepcidina y metodos de uso.
|
EP2474556A3
(de)
|
2007-03-14 |
2012-10-17 |
Novartis AG |
APCDD1-Inhibitoren zur Behandlung, Diagnose und Erkennung von Krebs
|
CA2707840A1
(en)
*
|
2007-08-20 |
2009-02-26 |
Allozyne, Inc. |
Amino acid substituted molecules
|
DK2222706T4
(en)
|
2007-12-14 |
2016-11-21 |
Novo Nordisk As |
Antibodies that bind to NKG2D and its use
|
US9138403B2
(en)
|
2007-12-20 |
2015-09-22 |
Merck Serono Sa |
PEG-interferon-beta formulations
|
US8414893B2
(en)
|
2007-12-21 |
2013-04-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
EP2628753A1
(de)
|
2008-01-24 |
2013-08-21 |
Novo Nordisk A/S |
Humanisierter monoklonaler Anti-human-NKG2A-Antikörper
|
US9175078B2
(en)
|
2008-01-25 |
2015-11-03 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
US9315577B2
(en)
|
2008-05-01 |
2016-04-19 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
SG10201706350PA
(en)
|
2008-07-16 |
2017-09-28 |
Inst For Res In Biomedicine |
Human cytomegalovirus neutralizing antibodies and use thereof
|
EP2960250A1
(de)
|
2008-07-16 |
2015-12-30 |
Institute for Research in Biomedicine |
Das humane cytomegalovirus neutralisierende antikörper und anwendung davon
|
JP5607620B2
(ja)
*
|
2008-07-25 |
2014-10-15 |
インスティテュート・フォー・リサーチ・イン・バイオメディシン |
抗a型インフルエンザウイルス中和抗体およびその使用
|
US8871207B2
(en)
|
2008-07-25 |
2014-10-28 |
Humabs, LLC |
Neutralizing anti-influenza A virus antibodies and uses thereof
|
CA2736314A1
(en)
*
|
2008-09-08 |
2010-03-11 |
Ottawa Hospital Research Institute |
Periostin-induced pancreatic regeneration
|
JP2012502906A
(ja)
*
|
2008-09-17 |
2012-02-02 |
ネクター セラピューティックス |
オリゴマー−プロテアーゼ阻害剤コンジュゲート
|
JP5814790B2
(ja)
|
2008-10-13 |
2015-11-17 |
インスティテュート・フォー・リサーチ・イン・バイオメディシンInstitute For Research In Biomedicine |
デングウイルス中和抗体およびその使用
|
UA109633C2
(uk)
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
CA2755133A1
(en)
|
2009-03-20 |
2010-09-23 |
Amgen Inc. |
Selective and potent peptide inhibitors of kv1.3
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
US9885711B2
(en)
|
2009-09-25 |
2018-02-06 |
Xoma Technology Ltd. |
Screening methods
|
CN102040822B
(zh)
*
|
2009-10-10 |
2012-11-14 |
复旦大学 |
一种细菌视紫红质/嵌段共聚物水凝胶复合材料及其制备方法
|
AR079114A1
(es)
|
2009-11-20 |
2011-12-28 |
Amgen Inc |
Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
|
US20110212106A1
(en)
|
2010-01-20 |
2011-09-01 |
Institute For Research In Bioscience |
Hiv-1 neutralizing antibodies and uses thereof
|
NZ602294A
(en)
|
2010-03-10 |
2015-04-24 |
Genmab As |
Monoclonal antibodies against c-met
|
EP2575880B1
(de)
|
2010-05-27 |
2019-01-16 |
Genmab A/S |
Monoklonale antikörper gegen her2-epitop
|
CN103154035B
(zh)
|
2010-05-27 |
2017-05-10 |
根马布股份公司 |
针对her2的单克隆抗体
|
PT2580243T
(pt)
|
2010-06-09 |
2020-01-22 |
Genmab As |
Anticorpos contra cd38 humana
|
PT2582728T
(pt)
|
2010-06-15 |
2017-11-23 |
Genmab As |
Conjugados fármaco-anticorpo humano contra fator tecidual
|
MX360946B
(es)
|
2010-09-22 |
2018-10-29 |
Amgen Inc Star |
Inmunoglobulinas portadoras y usos de las mismas.
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
NZ611176A
(en)
|
2010-12-02 |
2015-07-31 |
Bionor Immuno As |
Peptide scaffold design
|
CN108939067A
(zh)
|
2010-12-21 |
2018-12-07 |
瑟莱克斯制药公司 |
抗p-选择素抗体及其使用和鉴定方法
|
MX346475B
(es)
|
2011-01-06 |
2017-03-22 |
Bionor Immuno As |
Peptidos inmunogenicos monomericos y multimericos.
|
US9499610B2
(en)
|
2011-04-08 |
2016-11-22 |
H. Lundbeck A/S |
Antibodies specific to pyroglutamated Aβ
|
CA2832387A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecifc antibodies against her2
|
KR102148982B1
(ko)
|
2011-06-03 |
2020-08-27 |
조마 테크놀로지 리미티드 |
Tgf-베타에 특이적인 항체
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
ES2841899T3
(es)
|
2011-07-18 |
2021-07-12 |
Inst Res Biomedicine |
Anticuerpos neutralizantes del virus de la influenza A y usos de los mismos
|
PL2828293T3
(pl)
|
2012-03-20 |
2018-03-30 |
Humabs Biomed S.A. |
Przeciwciała, które neutralizują RSV, MPV i PVM oraz ich zastosowania
|
WO2013182661A1
(en)
|
2012-06-06 |
2013-12-12 |
Bionor Immuno As |
Peptides derived from viral proteins for use as immunogens and dosage reactants
|
SG10201605703TA
(en)
|
2012-07-06 |
2016-09-29 |
Genmab Bv |
Dimeric protein with triple mutations
|
EP3632462A1
(de)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimerprotein mit dreifacher mutation
|
UA105278C2
(ru)
|
2012-09-06 |
2014-04-25 |
Інститут Біології Клітини Нан України |
Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
|
CN113735967A
(zh)
|
2013-01-10 |
2021-12-03 |
根马布私人有限公司 |
人类IgG1 FC区变体及其用途
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
BR112015020587A2
(pt)
|
2013-03-14 |
2017-10-10 |
Regeneron Pharma |
proteínas de fusão de apelina e suas utilizações
|
US9657098B2
(en)
|
2013-03-15 |
2017-05-23 |
Intrinsic Lifesciences, Llc |
Anti-hepcidin antibodies and uses thereof
|
CN118005782A
(zh)
|
2013-10-02 |
2024-05-10 |
免疫医疗有限责任公司 |
中和抗甲型流感抗体及其用途
|
US10183078B2
(en)
|
2014-01-17 |
2019-01-22 |
Cedars-Sinai Medical Center |
Receptor targeting constructs and uses thereof
|
JP6913018B2
(ja)
|
2014-07-08 |
2021-08-04 |
ニューヨーク・ユニバーシティ |
タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
|
RS60012B1
(sr)
|
2014-07-11 |
2020-04-30 |
Genmab As |
Antitela koja vezuju axl
|
CN113563462A
(zh)
|
2014-07-15 |
2021-10-29 |
免疫医疗有限责任公司 |
中和抗乙型流感抗体及其用途
|
WO2016013751A1
(ko)
|
2014-07-22 |
2016-01-28 |
주식회사 레모넥스 |
생리활성 물질 또는 단백질 전달용 조성물 및 이의 용도
|
AU2015294389B2
(en)
|
2014-07-24 |
2021-04-29 |
Genentech, Inc. |
Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
|
US10323088B2
(en)
|
2014-09-22 |
2019-06-18 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
WO2016055950A1
(en)
|
2014-10-08 |
2016-04-14 |
Novartis Ag |
Combination of human cytomegalovirus neutralizing antibodies
|
AU2015335029B2
(en)
|
2014-10-24 |
2021-09-23 |
Astrazeneca Ab |
Combination
|
CN107106669A
(zh)
|
2014-11-04 |
2017-08-29 |
南加利福尼亚大学 |
用于治疗过度表达HIF‑1α的癌症的组合物和方法
|
WO2016075546A2
(en)
|
2014-11-14 |
2016-05-19 |
Antonio Lanzavecchia |
Antibodies that neutralize ebola virus and uses thereof
|
BR122020023406B1
(pt)
|
2014-11-18 |
2023-10-31 |
Institut Pasteur |
Anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus, moléculas de ácido nucleico, vetor, célula isolada, composição farmacêutica, usos dos mesmos, e kit de partes
|
EP3916017A1
(de)
|
2014-12-22 |
2021-12-01 |
PD-1 Acquisition Group, LLC |
Anti-pd-1-antikörper
|
PL3277725T3
(pl)
|
2015-03-30 |
2021-06-14 |
Regeneron Pharmaceuticals, Inc. |
Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gamma
|
US10441644B2
(en)
|
2015-05-05 |
2019-10-15 |
The Regents Of The University Of California |
H3.3 CTL peptides and uses thereof
|
EP3292139B1
(de)
|
2015-05-05 |
2020-10-28 |
The Regents of The University of California |
H3.3-ctl-peptide und verwendungen davon
|
US20160347848A1
(en)
|
2015-05-28 |
2016-12-01 |
Medimmune Limited |
Therapeutic combinations and methods for treating neoplasia
|
SI3303384T1
(sl)
|
2015-06-01 |
2021-11-30 |
Medimmune Llc |
Nevtralizirajoče vezavne molekule proti-influenci in njihova uporaba
|
US20180179274A1
(en)
|
2015-06-26 |
2018-06-28 |
Institute For Research In Biomedicine |
Proteins comprising a mutated lair-1 fragment and uses thereof
|
CN108368171A
(zh)
|
2015-07-10 |
2018-08-03 |
根马布股份公司 |
用于癌症治疗的axl特异性抗体-药物缀合物
|
JO3711B1
(ar)
|
2015-07-13 |
2021-01-31 |
H Lundbeck As |
أجسام مضادة محددة لبروتين تاو وطرق استعمالها
|
GB201512215D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
GB201512203D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
WO2017027685A2
(en)
|
2015-08-13 |
2017-02-16 |
New York University |
Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
|
FI3334761T3
(fi)
|
2015-08-13 |
2023-08-14 |
Univ New York |
Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa
|
WO2017059878A1
(en)
|
2015-10-07 |
2017-04-13 |
Humabs Biomed Sa |
Antibodies that potently neutralize hepatitis b virus and uses thereof
|
US9884920B2
(en)
|
2015-10-09 |
2018-02-06 |
Florida State University Research Foundation, Inc. |
Antibodies specific for 4,6-diamino-5-(formamido)pyrimidine and uses thereof
|
AR108824A1
(es)
|
2015-11-21 |
2018-10-03 |
Fundacio Privada Inst De Recerca De La Sida Caixa Irsicaixa |
Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria
|
KR20180101436A
(ko)
|
2016-01-13 |
2018-09-12 |
메디뮨 엘엘씨 |
인플루엔자 a의 치료 방법
|
JP7029415B2
(ja)
|
2016-07-12 |
2022-03-03 |
ハー・ルンドベック・アクチエゼルスカベット |
過リン酸化タウに特異的な抗体およびその使用方法
|
WO2018010789A1
(en)
|
2016-07-13 |
2018-01-18 |
Humabs Biomed Sa |
Novel antibodies specifically binding to zika virus epitopes and uses thereof
|
JP2019537621A
(ja)
|
2016-10-04 |
2019-12-26 |
フェアバンクス ファーマシューティカルズ,インコーポレイテッド |
抗fstl3抗体およびその使用
|
CA3041988A1
(en)
|
2016-11-01 |
2018-05-11 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
CA3043651A1
(en)
|
2016-11-15 |
2018-05-24 |
H. Lundbeck A/S |
Agents, uses and methods for the treatment of synucleinopathy
|
AU2017373651B2
(en)
|
2016-12-05 |
2022-03-10 |
Nuritas Limited |
Compositions comprising peptide wkdeagkplvk
|
EP3329930A1
(de)
|
2016-12-05 |
2018-06-06 |
Nuritas Limited |
Pharmazeutische zusammensetzungen
|
EP3329905A1
(de)
|
2016-12-05 |
2018-06-06 |
Nuritas Limited |
Topische kosmetische zusammensetzungen enhaltend ein oligopeptid gegen die hautalterung
|
BR112018016717A2
(pt)
|
2016-12-16 |
2018-12-26 |
H Lundbeck As |
agentes, usos e métodos
|
US10364286B2
(en)
|
2016-12-22 |
2019-07-30 |
H. Lundbeck A/S |
Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
|
EP3565836A1
(de)
|
2017-01-04 |
2019-11-13 |
H. Lundbeck A/S |
Für hypophosphoryliertes tau spezifische antikörper zur behandlung von augenerkrankungen
|
WO2018143787A1
(ko)
|
2017-02-06 |
2018-08-09 |
주식회사 레모넥스 |
생리활성물질 전달체
|
CN110475546A
(zh)
|
2017-02-06 |
2019-11-19 |
雷莫内克斯生物制药有限公司 |
生理活性物质载体
|
EA201992434A1
(ru)
|
2017-04-19 |
2020-03-30 |
Инститьют Фор Рисерч Ин Байомедисин |
Новые противомалярийные вакцины и антитела, связывающиеся со спорозоитами плазмодия
|
JP2020519309A
(ja)
|
2017-05-10 |
2020-07-02 |
アルバジュナ・セラピューティクス・エセ・エレ |
高い二重のHIV抗ウイルス及び免疫調節活性を有するFc融合タンパク質誘導体
|
US10894833B2
(en)
|
2017-07-20 |
2021-01-19 |
H. Lundbeck A/S |
Agents, uses and methods for treatment
|
WO2019042555A1
(en)
|
2017-08-31 |
2019-03-07 |
Humabs Biomed Sa |
MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
|
US11530132B2
(en)
|
2017-09-05 |
2022-12-20 |
Lemonex Inc. |
Composition comprising porous silica particles carrying a cell fate modulating factor
|
MA51666A
(fr)
|
2018-01-24 |
2020-12-02 |
Genmab Bv |
Variants polypeptidiques et leurs utilisations
|
WO2019160976A1
(en)
|
2018-02-14 |
2019-08-22 |
Viela Bio, Inc. |
Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases
|
KR20210005051A
(ko)
|
2018-04-30 |
2021-01-13 |
다케다 야쿠힌 고교 가부시키가이샤 |
카나비노이드 수용체 유형 1 (cb1) 결합 단백질들과 이의 용도
|
EP3820498A1
(de)
|
2018-06-14 |
2021-05-19 |
University College Cork-National University of Ireland Cork |
Peptid zur krankheitsbehandlung
|
WO2020021061A1
(en)
|
2018-07-26 |
2020-01-30 |
Pieris Pharmaceuticals Gmbh |
Humanized anti-pd-1 antibodies and uses thereof
|
CN118108836A
(zh)
|
2018-12-19 |
2024-05-31 |
胡默波斯生物医学公司 |
中和乙型肝炎病毒的抗体和其用途
|
CA3127113A1
(en)
|
2019-01-30 |
2020-08-06 |
Dongxu Sun |
Anti-gal3 antibodies and uses thereof
|
AU2020248645A1
(en)
|
2019-03-27 |
2021-10-28 |
Tigatx, Inc. |
Engineered IgA antibodies and methods of use
|
MX2021012171A
(es)
|
2019-04-09 |
2021-12-10 |
Abcuro Inc |
Anticuerpos reductores del miembro 1 de la subfamilia g de receptores similares a la lectina de linfocitos citoliticos (klrg1).
|
US20220287347A1
(en)
|
2019-08-20 |
2022-09-15 |
Nuritas Limited |
Peptides for treating muscle atrophy
|
EP3783012A1
(de)
|
2019-08-20 |
2021-02-24 |
Nuritas Limited |
Antimikrobielles peptid
|
BR112022003698A2
(pt)
|
2019-08-29 |
2022-05-24 |
Vir Biotechnology Inc |
Método de tratamento de uma infecção pelo vírus da hepatite b e composição farmacêutica
|
AU2020370733A1
(en)
|
2019-10-22 |
2022-05-05 |
Nuritas Limited |
Treatment of non-alcoholic fatty liver disease
|
EP3862014A1
(de)
|
2020-02-07 |
2021-08-11 |
Nuritas Limited |
Behandlung von panx1-assoziierten erkrankungen
|
US20230109142A1
(en)
|
2020-02-14 |
2023-04-06 |
Immunor As |
Corona virus vaccine
|
JP2023531520A
(ja)
|
2020-06-24 |
2023-07-24 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
操作されたb型肝炎ウイルス中和抗体およびその使用
|
EP4276113A1
(de)
|
2021-01-08 |
2023-11-15 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Spezifisch an cd47 bindender antikörper und antigenbindendes fragment davon
|
EP4276111A1
(de)
|
2021-01-08 |
2023-11-15 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Antikörper mit spezifischer bindung an 4-1bb und antigenbindendes fragment des antikörpers
|
WO2022148414A1
(zh)
|
2021-01-08 |
2022-07-14 |
北京韩美药品有限公司 |
特异性结合pd-l1的抗体及其抗原结合片段
|
EP4284428A1
(de)
|
2021-01-26 |
2023-12-06 |
VIR Biotechnology, Inc. |
Zusammensetzungen und verfahren zur behandlung von hepatitis-b-virusinfektionen
|
KR20230162798A
(ko)
|
2021-03-26 |
2023-11-28 |
압큐로, 인크. |
항-klrg1 항체
|
WO2022204529A1
(en)
|
2021-03-26 |
2022-09-29 |
Abcuro, Inc. |
Anti-klrg1 antibodies
|
WO2022212836A1
(en)
|
2021-04-01 |
2022-10-06 |
Pyxis Oncology, Inc. |
Gpnmb antibodies and methods of use
|
JP2024514194A
(ja)
|
2021-04-14 |
2024-03-28 |
ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド,コーク |
変形性関節症の治療に使用するためのpsg1
|
JP2024514195A
(ja)
|
2021-04-14 |
2024-03-28 |
ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド,コーク |
脳血管イベントおよび神経障害の治療
|
WO2023009498A1
(en)
|
2021-07-26 |
2023-02-02 |
Abcuro, Inc. |
Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
|
WO2023105281A1
(en)
|
2021-12-11 |
2023-06-15 |
Fundaciò Privada Institut De Recerca De La Sida-Caixa |
Soluble tigit recombinant proteins
|
WO2024078729A1
(en)
|
2022-10-14 |
2024-04-18 |
University College Cork - National University Of Ireland, Cork |
Placenta expressed proteins for use in the treatment of tendon injury
|